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Abstract
Introduction and hypothesis The coronavirus (COVID-19) pandemic has impacted health systems worldwide. There is a
continuing need for clinicians to adapt practice to facilitate timely provision of medical care, whilst minimising horizontal
transmission. Guidance and recommendations are increasingly available, and this rapid review aimed to provide a timely
evidence synthesis on the current recommendations surrounding urogynaecological care.
Methods We performed a literature review using PubMed/Medline, Embase and Cochrane and a manual search of national and
international societies for management recommendations for urogynaecological patients during the COVID-19 pandemic.
Results Nine guidance documents and 17 articles, including 10 reviews, were included. Virtual clinics are recommended for new
and follow-up patients, to assess and initiate treatment, as well as triage patients who require face-to-face appointments. Outpatient
investigations such as urodynamics and cystoscopy for benign indications can be deferred. Prolapse and continence surgery should
be suspended, except in specific circumstances such as procidentia with upper tract complications and failed pessaries. There is no
evidence to support a particular route of surgery, but recommendations are made to minimise COVID-19 transmission.
Conclusions Urogynaecological patients face particular challenges owing to inherent vulnerabilities of these populations.
Behavioural and medical therapies should be recommended as first line options and initiated via virtual or remote clinics, which
are integral to management during the COVID-19 pandemic. Expanding the availability and accessibility of technology will be
increasingly required. The majority of outpatient and inpatient procedures can be deferred, but the longer-term effects of such
practices are unclear.
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Introduction
Coronavirus (COVID-19) disease caused by the SARS-CoV-2
virus was first declared as a pandemic by the World Health
Organization (WHO) on 11 March 2020 [1]. Since then it has
continued to rapidly spread worldwide impacting all aspects of
life, not least medical care and how clinicians assess and treat
patients. Medical providers worldwide have been required to
adapt and streamline services to minimise unwarranted, multi-
ple healthcare facility attendances and patient contact where
possible, by conducting remote consultations, delaying non-
urgent visits and optimising provision of one-stop services.
The urogynaecology scope of practice involves, to a signifi-
cant proportion, care and management of elderly and vulnerable
patients and therefore these measures are of particular impor-
tance. As the pandemic continues, national and international
societies and organisations have published guidance for manage-
ment mainly based on consensus and expert advice given that
evidence base to support recommendations is still scarce [2–5].
Rapid reviews are a method of knowledge or evidence
synthesis [6] to produce information in a more timely manner
than traditional systematic reviews [7]; therefore, they are
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particularly useful for new and emerging topics. Rapid re-
views involve an expedited process with omission of certain
steps usually performed in a systematic review.
Given the rapid evolution of evidence, recommendations,
policies and clinical management adaptations, a rapid review
on the current evidence and recommendations is highly war-
ranted. Since the COVID-19 pandemic was declared, several
publications have appeared providing narrative reviews in order
to bring all the relevant information from the guidelines togeth-
er in one document, to support patient care [8–10]. These stud-
ies summarise and review published guidelines, original stud-
ies, consensus statements, opinions and comments in peer-
reviewed journals, and professional organisations and societies.
The aim of this rapid review is to systematically review and
evaluate the available evidence from published research, as
well as to collate guidelines and recommendations in order
to provide guidance on the management of urogynaecological
conditions and clinical practices in response to the COVID-19
pandemic. This review has been undertaken by CHORUS, An
International Collaboration for Harmonising Outcomes,
Research and Standards in Urogynaecology and Women’s
Health (i-chorus.org).
Materials and methods
We performed a literature review using the OvidSP search
platform and interrogating through this the databases
PubMed/Medline, Embase and Cochrane using keywords
and MeSH terms including: COVID-19, SARS-CoV-2, coro-
navirus, incontinence, pelvic organ prolapse, vaginal prolapse,
uterine prolapse, cystocele, rectocele, bladder pain, childbirth
trauma, perineal trauma, perineal laceration, urogynaecology,
urogynecology, overactive bladder (OAB), recurrent cystitis,
recurrent urinary tract infections (UTIs); (Appendix 1).
Literature searches were conducted from 1 January to 22
September 2020. We searched the references of the relevant
studies manually using the backward snowballing method
[11] in order to identify additional eligible references and stud-
ies. In addition, a manual search was conducted of national and
international specialist societies and organisations in order to
identify practice guidance. We searched the websites of the
International Urogynecological Association (IUGA),
International Continence Society (ICS), European Association
of Urology (EAU), British Society of Urogynaecology
(BSUG), Royal College of Obstetricians and Gynaecologists
(RCOG), Royal Australian and New Zealand College of
Obstetricians and Gynaecologists (RANZCOG), American
Urological Association (AUA), American Urogynecologic
Society (AUGS), Asia-Pacific Urogynecology Association
(APUGA), Urogynecologist Asia (UG-Asia), Urological
Association of Asia (UAA), South African Urogynaecological
Association (SAUGA) and Pan African Urological Association
(PAUSA). The latest version of guidelines was used in cases
where more than one guideline or update was available. The
final decision about the inclusion of guidelines and published
articles was based on authors’ consensus.
All searches were restricted to English-language publications
or those with the facility to translate to English, guidelines and
best-practice statements. We did not exclude original articles,
comments or perspectives. Inclusion criteria were the presence
in the articles of guidance or practical advice for themanagement
of urogynaecology patients during the COVID-19 pandemic.
Exclusion criteria were non-English-language articles with
translation not readily available, guidelines unavailable to the
public in full text, not involving urogynaecology care or not
involving urogynaecology care during the COVID-19 pandemic.
Study selection was conducted in stages. Following title
screening, the abstracts of all articles in the database were
examined. Two reviewers scrutinised the full text of each
article and evaluated the studies potentially eligible for inclu-
sion against the inclusion criteria. Discrepancies regarding
inclusion or exclusion were resolved through discussion.
Ethical approval was not required for this review. One re-
viewer extracted relevant data from all eligible articles. The
content of each guideline or article was tabulated including the
title of the guidance or article, issuing association or journal,
and date of publication.
The quality of guidelines was evaluated using the Appraisal
of Guidelines for Research and Evaluation (AGREE II) instru-
ment [12] and the quality of reviews assessed using Scale for
the Assessment of Narrative Review Articles (SANRA) [13].
Results
Nine guidance documents and 17 articles, 10 of which are
reviews, were included (Fig. 1; Table 1).
Quality assessment of guidelines was performed using
Appraisal of Guidelines for Research and Evaluation II instru-
ment (AGREEII). Overall assessment scores are shown in
Table 1 (1 lowest quality to 7 highest quality). See
Appendix 2 for individual domain scores.
Review articles were assessed using the Scale for the
Assessment of Narrative ReviewArticles (SANRA)with amax-
imum score of 12. See Appendix 3 for the full SANRA scale.
Recommendations
All 12 articles and guidelines that included outpatient clinic rec-
ommendations stated that virtual clinics should be used to min-
imise horizontal transmission. Virtual clinics can be used for all
non-urgent indications such as urinary incontinence and pro-
lapse, and for both initial consultations and follow-up appoint-
ments. Patient satisfaction is unaffected and clinic attendance
may be increased owing to a reduction in non-attendance [19].
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When used for postoperative follow-up there is no increase in
adverse outcomes [19]. For patients awaiting surgery, virtual
clinics can be conducted to rediscuss alternative therapies.
During virtual clinics, patients can be triaged and limited
face-to-face appointments arranged if necessary. When seen
face to face, appropriate screening should be undertaken, per-
sonal protective equipment (PPE) worn, physical distance
maintained, and sanitation available [31].
It has been reported that COVID-19 transmission could be
as high as 12.8% at a physical distance of less than 1 m
compared with 2.6% at a distance of more than 1 m, reflecting
the importance of maintaining physical distance [34].
In keeping with these findings, the Scientific Advisory
Group for Emergencies (SAGE), who provide scientific
and technical advice to support government decision
makers in the UK, reported that COVID-19 transmission
could be 2-10 times higher at a physical distance of 1 m
compared with 2 m [35]. See Table 2 for a summary of
guidance for virtual clinics and inpatient admissions.
Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram
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Table 1 Included articles and guidelines
Reference Date Title Article type Topics included Quality
assessment
score
[14] 23 March Urology practice during
the COVID-19 pandemic
Guidance Surgical prioritisation 5
Surgical techniques to minimise exposure
Outpatient procedures




Guidance Laparoscopic and hysteroscopic surgery 4
Limiting horizontal spread of COVID-19
Optimising patient outcomes
[4] 27 March Joint Statement on minimally
invasive gynecologic surgery
during the COVID-19 pandemic
Guidance Limiting horizontal spread of COVID-19 5
Endoscopic surgery
Vaginal and open abdominal surgery
[15] 3 April COVID-19: outpatient services;
office consultations and
procedures
Guidance Outpatient clinics and procedures 4
[3] 9 April BSUG guidance on management
of urogynaecological conditions
and vaginal pessary use during
the Covid 19 pandemic






[16] 20 April COVID-19: recommendations
for functional urology















[18] 28 April Joint Statement on re-introduction
of hospital and office-based
procedures in the COVID-19
climate for the practicing
urogynecologist and gynecologist
Guidance Surgical prioritisation 5
Inpatient and outpatient procedures
[5] July An organisation-wide collaborative
effort to adapt the EAU
guidelines recommendations to
the COVID-19 era
Guidance Surgical prioritisation 6
Management of lower urinary tract
symptoms
[19] 27 April A guide for urogynecologic
patient care utilizing telemedicine
during the COVID-19 pandemic:
review of existing evidence
Review Virtual clinics 12/12




[20] 24 May Forecasting the future of urology
practice: a comprehensive review
of the recommendations by
international and European
associations on priority procedures






[21] 29 May Practical recommendations for
gynecologic surgery during
the COVID-19 pandemic
Review Surgical prioritisation 8/12
[22] 17 June Guidance for gynecologists
utilizing telemedicine during
COVID-19 pandemic based
on expert consensus and
rapid literature reviews
Review Telemedicine 12/12
[23] 18 June Systematic review Telemedicine 12/12
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Table 1 (continued)
Reference Date Title Article type Topics included Quality
assessment
score
Telehealth in urology: a systematic
review of the literature. How
much can telemedicine be
useful during and after the
COVID-19 pandemic?
Management of lower urinary
tract symptoms
[8] 23 June COVID-19 and gynecological
cancer: a review of the
published guidelines








[25] 25 August How did COVID-19 pandemic
change the way we attend
the patients in an
urogynaecological unit
Review Assessment and management of





[26] 2 September A lasting impression: telemedicine




[27] 15 September A systematic review on guidelines
and recommendations for
urology standard of care during
the COVID-19 pandemic
Review Uro-oncology 12/12
Endoscopic and robotic surgery
Outpatient procedures
[28] 15 September Management of female and
functional urology patients
during the COVID pandemic
Review Surgical prioritisation 11/12
Surgical techniques to minimise
exposure
Management of lower urinary tract
symptoms
[29] March Resumption of elective surgery
following COVID-19 outbreak,
guideline for female pelvic
medicine and surgery
Editorial Surgical prioritisation




[31] 11 June Technology-based management
of neurourology patients in the
COVID-19 pandemic: is this




[18] 1 July Widespread postponement of
functional urology cases
during the COVID-19 pandemic:
rationale, potential pitfalls, and
future consequences




[32] 2 July Virtual consent for virtual patients:
benefits of implementation in a
peri- and post-COVID-19 era
Editorial Virtual clinic and consent
[33] 17 July Neuro-urology during the
COVID-19 pandemic: triage
and priority of treatments
Letter to editor Voiding dysfunction
Neurogenic bladder
RCOG Royal College of Obstetricians and Gynaecologists, BSGE British Society for Gynaecological Endoscopy, AUGS American Urogynecologic
Society, RANZCOG Royal Australian and New Zealand College of Obstetricians and Gynaecologists, BSUG British Society of Urogynaecology, EAU
European Association of Urology
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Table 2 Summary of guidance for virtual clinics and inpatient admissions
Reference Virtual clinics/telemedicine Outpatient department, inpatient admissions
[17] Postoperative follow-up can be virtual
Non-inferior for patient satisfaction, complication rates and adverse events
[31] Cancel all face-to-face outpatient appointments
Virtual consultations where possible
Can identify patients requiring urgent consultation
[28] Initial and follow-up consultations can be virtual If seeing face-to-face, patient to wear surgical mask and
gloves, clinician to wear apron, surgical mask, visor and
gloves
Triage patients for face-to-face consultation Invasive tests: clinician wears N95 mask, impermeable gown,
gloves and visor
[19] Virtual clinics: patient satisfaction unaffected, can increase clinic
attendance
Postoperative virtual clinics: no increase in adverse outcomes or primary
care visits
Native tissue prolapse repair and mid-urethral sling with no incontinence
can be safely followed up in virtual clinic
Triage all patients for virtual clinic: established patients not requiring
examination, new patients who would benefit from non-surgical
treatment, postponed patients awaiting surgery to rediscuss alternative
therapies
Provide patient information leaflets from established bodies
[8] Virtual clinics Physical distancing
Sanitisation areas
Work from home Limit friends and family accompanying
Minimise face-to-face Adequate PPE
[3] Virtual clinic for pessary follow-up
Triage patients: see semi-urgently, within 30 days or delayed review
[16] Use telemedicine
Avoid face-to-face where possible
[26] Telemedicine to minimise exposure
[22] Use telemedicine
Avoid face-to-face where possible
Use telemedicine to assess need for face-to-face review
Postoperative follow-up: equal patient-related outcomes with telemedicine
compared with face-to-face
[36] Use video or teleconsults for all non-urgent indications
[5] Use telemedicine to allow physical distancing and minimise footfall
[18] Telemedicine whilst awaiting surgery to help with symptom management
[15] Essential staff only in clinic rooms
Discourage accompanying persons
Physical distancing
Cleaning surfaces with appropriate disinfectant
Handwashing before and after patient contact
Waiting and clinic room with appropriate safe spacing
COVID-19 positive or those in isolation should not be seen
face-to-face. If no option, then wear appropriate PPE
If face-to-face appointment, screen all patients and accompa-
nying persons for symptoms, travel and exposure
PPE personal protective equipment
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Table 3 Summary of guidance for urinary incontinence and prolapse
Reference OAB, UUI and SUI Prolapse and pessaries
[17] Virtual consultations Virtual consultations
Use validated questionnaires for urinary symptoms Use validated questionnaires for prolapse
Lifestyle measures, PFMT as first line If mild symptoms: PFMT
Consider starting antimuscarinics/B3 agonist/vaginal oestrogen If severely affecting bladder/bowel function and/or ulcer
present, may require face-to-face appointment
Regular follow-up, i.e. 4 weeks after starting antimuscarinics Pessaries: arrange face-to-face if bleeding or pain symptoms
Yearly review of long-term antimuscarinic Can delay pessary change for an additional 3 months after
routine 6-month interval, then review
For SUI consider incontinence pessaries
[33] For neurogenic SUI: device implantation can be deferred until safe, no time
limit, use pads in interim
Erosion from implants requiring removal of prosthesis: defer up to 4 weeks
Neurogenic bladder with risk factors for upper renal tract, e.g. DSD: Botox
can be deferred up to 8 weeks
Neurogenic bladder without risk factors for upper renal tract: can defer Botox
during pandemic, no time limit
[31] Can teach and monitor PFMT via video consultation
[28] Delay all continence procedures until after COVID crisis
Manage as outpatients with conservative and medical therapy
Delay all new sacral neuromodulation until end of COVID crisis
Remove percutaneous nerve evaluation lead in outpatient clinic if one in situ
If infected implant treat with intravenous antibiotics; if severe infection
remove urgently, i.e. <2 weeks
Conservative and medical treatments for SUI and OAB/UUI
[27] Stage 2 neuromodulation: no delay owing to risk of infection Pessary changes: defer for 3–6 months
[19] Behavioural measures Virtual consultations
Self-inserted incontinence tampons or pessaries can be recommended Online instructions for PFMT
Patients having invasive treatment, e.g. intravesical Botox, can restart
antimuscarinic/mirabegron until service restarts
Behavioural measures, e.g. weight loss, Kegel exercises,
PFMT
Short-term antimuscarinic unlikely to cause dementia therefore can use in
elderly if required
Smart phone apps, e.g. for Kegel training
Home biofeedback devices
Pessaries: encourage self-cleaning at home
Can safely delay change up to 6 months
Consider vaginal oestrogen and empiric treatment for
bacterial vaginosis
If bleeding/discharge can remove and observe for voiding
dysfunction prior to clinic review
[3] Initial virtual consultations Initial virtual consultations
Can commence treatment remotely Procidentia causing bowel/urinary problems need early re-
view within 30 days
Provide patients with information resources Pessaries: face-to-face review within 7 days if symptoms
suggestive of fistulation
Pessaries: face-to-face review within 30 days if bleeding/-
pain/ulceration
Pessaries: refer via local PMB cancer pathway if PMB with
pessary and uterus in situ
Ring pessaries: can defer change up to 6 months
Shaatz, shelf, Gelhorn, double pessaries: defer for a
maximum of 3 months
Patients to be given contact numbers in the case of
symptoms of ulceration
[16] Encourage conservative and medical treatments Virtual clinics
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Of 15 articles and guidelines providing recommendations
regarding the management of urinary incontinence and OAB,
12 advise behavioural therapies as the first line.
Two recommend use of smart phone apps to supplement
education, for example, for Kegel exercises [19, 26].
Suspension of invasive therapies for urinary incontinence is ad-
vised, except where stage 1 sacral neuromodulation is in place or
in cases of neurogenic bladder with a high risk of upper renal
tract complications [33]. Pelvic floor muscle training is recom-
mended as the first-line for symptomatic prolapse [16, 17, 19, 23,
26]; however, in one editorial, suspension of pelvic floor muscle
training is suggested to maintain physical distancing [36].
Use of pessaries is recommended, whilst prolapse surgery
is deferred [16, 26, 36], and the pessary change interval can be
extended by 3–6 months unless the patient has symptoms of
ulceration or fistulation [3, 24, 27]. See Table 3 for a summary
of guidance for urinary incontinence and prolapse.
Acute retention or a blocked catheter warrants urgent re-
view for catheterisation [20].
If an indwelling catheter is in situ, routine changes can be
deferred for 2–4 weeks, unless the patient has a history of
difficult changes or recurrent UTIs [24]. Deferring suprapubic
catheter changes [3, 20] for up to 3 months has been suggested
and changes in the community rather than in the hospital set-
ting are preferred [3, 36].
Urinary tract infections can be managed via virtual consul-
tation [17, 19, 23, 25]. If the patient has recurrent UTIs con-
servative measures and non-antibiotic therapies should be en-
couraged [17]. If antibiotics are required, they should be pre-
scribed according to previous culture results. Face-to-face re-
view should be arranged if the patient has complicated UTI or
is refractory to treatment [19]. See Table 4 for a summary of
voiding dysfunction and urinary tract infection.
Gross haematuria requires urgent investigation with
cystoscopy; however, microscopic haematuria investiga-
tions can be deferred. A systematic review of telemed-
icine in urology, however, reported that data indicate
that virtual clinics for initial evaluation are feasible, ef-
fective, and associated with a high degree of patient
satisfaction [23].
Bladder pain syndrome investigations should be deferred,
but oral treatments can be started [5, 28].
Fourteen articles reported recommendations for outpatient
procedures, including cystoscopy, intravesical Botox and
Table 3 (continued)
Reference OAB, UUI and SUI Prolapse and pessaries
SUI: all new patients with signs of retention and overflow, see face-to-face for
PVR with external probe
If grade 4 prolapse, consider US KUB
Favour pessary management
Consider surgery if stage 4 prolapse, failed pessaries and
obstructive renal failure
[26] Non-surgical options as first line whilst elective surgeries restricted Non-surgical options as first line whilst elective surgeries
are restricted
Medication management Smart phone apps
Smart phone apps
[25] Start all UI consultations using telemedicine
Supplement with use of mobile apps
Conservative measures—weight loss, bladder training, PFMT, Kegel exer-
cises ± medications
[36] Prescribe medication if required, all intravesical Botox postponed PFMT postponed to maintain physical distancing
PFMT postponed to maintain physical distancing Use pessary
Screen for red flag symptoms that may indicate bladder cancer and warrant
urgent cystoscopy
Urgent surgery if grade 4 prolapse/renal tract complications
and failed pessaries
Postpone SNS unless in test phase. If test phase, consider removal or
placement of pacemaker under local anaesthesia
[21] Use non-surgical management UI as advised by IUGA
[23] Evidence that behavioural measures and PFMT via video conferencing as
effective as face-to-face
Use of behavioural measures and PFMT
[5] Use conservative and medical treatments
[24] Can delay pessary change up to 3 months if no erosion or
ulcer
BSUGBritish Society of Urogynaecology, EAU European Association of Urology,OAB overactive bladder,UUI urge urinary incontinence, SUI stress urinary
incontinence, PFMT pelvic floor muscle training, DSD detrusor sphincter dyssynergia, PVR post-void residual volume, UI urinary incontinence, SNS sacral
nerve stimulation, IUGA International Urogynecological Association, US KUB ultrasound kidneys, ureters and bladder, PMB postmenopausal bleeding
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Table 4 Summary of voiding dysfunction and urinary tract infection
Reference Voiding dysfunction and catheters Urinary tract infection
[17] Severe voiding difficulty requires face-to-face appointment
for PVR ± ISC
Virtual consultations
Acute UTI: consider antibiotics based on symptoms and previous cultures
For recurrent UTI: non-antibiotics therapies, fluid advice, hygiene advice,
vaginal oestrogen low dose. Self start or rotating antibiotics. Safety net re:
ascending infection
[33] If chronic retention, no limit on deferral
IDC if ISC not available
[31] Can teach and monitor ISC via video consultation
[28] If acute retention, see face-to-face to assess for IDC or SPC ±
US KUB. Delay functional tests
Conservative and lifestyle measures: hygiene, non-antibiotics therapies,
low-dose antibiotics, vaginal oestrogen
Indwelling catheter: can defer by 4 weeks. Change earlier if
encrustations/blockages
[24] IDC: can defer change for 2–4 weeks unless history of diffi-
cult changes or recurrent UTI
[19] Encourage conservative measures to help void Culture with every episode and treat whilst awaiting results
Chronic retention >300 ml >6 months and acute retention:
face-to-face review
Previous cultures can guide prescribing
CISC preferable to IDC Remote prescribing effective, may have a negative impact on antibiotics
resistance. Fever and diabetes can indicate severe infection, may warrant
face to face appointment
Prescribing: nitrofurantoin or cotrimoxazole 3–7 days. Seven-day course for
the elderly and diabetic. Fluoroquinolone in complicated UTI to avoid
admission
Encourage conservative measures, e.g. cranberry, hydration, d-mannose,
vaginal oestrogen
Consider face-to-face review if refractory UTI with complications
[20] Acute retention: see face-to-face
Defer all SPC and IDC changes
[14] Acute retention: see face-to-face for IDC or SPC
[3] If acute retention need emergency/urgent review (within 12
hours) for IDC
If arranging TWOC, can defer on a case-by-case basis. If high
PVR, then teach CISC
Change of SPC can be delayed up to 3 months
Aim for SPC change in community not hospital setting
[25] Encourage conservative measures to help void, e.g.
double/triple voiding
Empirical treatment of UTI, including recurrent UTI
Chronic urinary retention, e.g. >300 ml for >6 months,
consider USS KUB and face-to-face consultation for ISC
or IDC
Electronic prescribing is effective and efficient
ISC preferable to IDC Resolution of symptoms indicative of cure
Teach ISC face-to-face, follow-up via virtual clinic
[36] Acute retention: place IDC or SPC, change regularly in the
community. Consider ISC if teaching and education
possible
[30] Obstructive urinary disorders—face-to-face clinics with
reduced capacity
[5] Voiding dysfunction: teach ISC or catheterise Sepsis/complicated UTI: high priority
Blocked catheter requires emergency review
[23] Can be managed safely and effectively using telemedicine
BSUGBritish Society of Urogynaecology, EAU European Association of Urology,PVR post-void residual volume, ISC intermittent self-catheterisation,
IDC indwelling urethral catheter, SPC suprapubic catheter, US KUB ultrasound of the kidneys, ureters and bladder, UTI urinary tract infection, CISC
clean intermittent self-catheterisation, TWOC trial without catheter
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Table 5 Summary of guidance for haematuria, bladder pain syndrome and outpatient procedures
Reference Haematuria and bladder pain syndrome Outpatient procedures
[17] Referral to secondary care if gross haematuria
[24] Gross haematuria: urgent cystoscopy, no deferring Delay urodynamics for 3–6 months
Microscopic haematuria with risk factors: can defer for up to 3 months
unless symptomatic
Microscopic haematuria and no symptoms: can defer for 3 months or
more
[27] Most but not all experts recommend urgent cystoscopy for macroscopic
haematuria. EAU and USANZ say it can be deferred for 1–2 months
Delay urodynamics. Time frame 1–6 months
Neurogenic intravesical Botox can be deferred for up to 4 weeks
Slings: clinical harm unlikely if postponed for 6 months
[20] Macroscopic haematuria: urgent cystoscopy Defer all cystoscopy for benign conditions
Microscopic: postpone
[23] Use telemedicine for initial haematuria consult and triage, then see
face-to-face if needed
[30] Continue cystoscopy for suspected cancer All outpatient cystoscopy suspended, continue only for suspected
cancer
[28] Delay BPS investigations until after COVID Do not commence new intravesical Botox treatments
Use oral medications, e.g. amitriptyline Delay intravesical Botox until end of COVID crisis
Continue bladder instillation if self-administered already
Defer if administered in hospital
[19] Consider face-to-face review if acute BPS flare requiring instillation
[5] Manage BPS conservatively All urodynamics postponed
Can offer amitriptyline
[31] All urodynamics postponed
Intravesical Botox can be carried out under local anaesthetic for
high-risk patients, e.g. autonomic dysreflexia
[14] Defer all cystoscopy for benign conditions
[3] Defer all outpatient treatments and investigations, i.e. cystoscopy
(non-cancer indications), bladder instillations, PTNS
[16] Intravesical Botox suspended unless neurological bladder with
upper tract risk
Cystoscopy: perform within 2 months if risk factors for cancer
and refractory OAB
[25] If planned intravesical Botox, can defer and restart
antimuscarinics/B3 agonists
[36] Intravesical Botox postponed. Consider continuing under local
anaesthesia for neurogenic bladder with renal tract
complications
[29] Intravesical Botox: non-essential, i.e., not time sensitive unless,
e.g. failure of conservative and progressive symptoms
[18] Tier 1 can delay beyond 12 weeks i.e. new Botox, new bulking,
new PTNS, urodynamics, pessary fittings, new PFMT
Tier 2 delay 4–12 weeks, e.g. repeat bulking agent, pessary
cleaning, PFMT follow-up
Tier 3 delayed for up to 4 weeks
Microscopic haematuria, established PTNS, bladder instillations
Tier 4 cannot be delayed
Macroscopic haematuria, new ISC instruction, voiding trial,
urinary retention, SPC follow-up
EAU European Association of Urology, BSUG British Society of Urogynaecology, USANZ Urological Society of Australia and New Zealand, BPS
bladder pain syndrome, PTNS percutaneous tibial nerve stimulation, OAB overactive bladder, PFMT pelvic floor muscle training, ISC intermitten self-
catheterisation
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Elective surgery and consent Surgical techniques to minimise horizontal transmission
[2] Outcomes worse for asymptomatic COVID-19 patients so surgery
may worsen or accelerate progression
No evidence of increased risk with laparoscopy when PPE worn
COVID-19 test all patients Vacuum suction devices for desufflation
14 days self-isolation preoperatively Use smoke extractor
Temperature on admission, defer if ≥37.3°C and retest after 14 days
Aim for local/regional anaesthetic if possible
Negative pressure in theatre
High frequency of filtered air exchange
Essential theatre staff only
Most experienced surgeon operating
PPE when GA: water repellent, long-sleeved gowns, eye and face
protection, gloves and FFP3 respirators
If pyrexial within 30 days screen and retest for COVID-19
[28] No contraindications to open, transurethral and vaginal procedures Low power setting for electrosurgery
Special care to be taken with laparoscopic and robotic procedures Avoid long desiccation times
Consider local anaesthesia where possible to minimise AGPs Closed smoke evacuation/filtration system with ULPA capability
COVID testing for any at-risk patient prior to surgery according to
local guidelines and availability
Laparoscopic suction to remove smoke and deflate abdomen
Most surgery is priority level 4 and can be deferred over 3 months Low intra-abdominal pressure 10–12 mmHg if feasible
Avoid rapid deflation
Minimise blood/fluid droplet spread
Be careful at time of instrument exchange and tissue extraction
Minimise CO2 leakage from trocars
[27] Endoscopic and robotic surgery: low electrocautery settings to
generate less smoke, lowest pressure insufflation, only essential
staff present in theatre, all staff in PPE
[20] Route of surgery at surgeon’s discretion Use closed system for insufflation
Smoke extractor
Adequate PPE
Use lowest intrabdominal pressure possible
Use lowest cautery setting possible
[8] Symptom screen and COVID test all patients preoperatively Shorter hospital stay
Clean COVID-free sites for surgery Can physical distance more than in open surgery
All elective surgery for benign indications suspended Risk of COVID transmission if not operating on GI tract during
laparoscopy is low
Low power diathermy. Closed smoke evacuation
Filtration system
Use suction to deflate abdomen
Low pressure 10–12 mmHg intraoperatively
Avoid rapid desufflation, minimise blood or fluid spray
Check seals around all reusable ports
GA in negative pressure room
[14] Experienced surgeon to minimise operating time Filter system to reduce viral release with gas
Clinical trials and trials of new technology to be postponed Low pressure pneumoperitoneum
COVID test all patients preoperatively Low bipolar cautery setting
Temperature testing and wearing masks on arrival
Reduce inpatient beds to allow physical distancing
[4] Suspend all elective surgery Low intra-abdominal pressure 10–12 mmHg






Elective surgery and consent Surgical techniques to minimise horizontal transmission
Preoperative screening on day of surgery, i.e. history examination Avoidance of long desiccation times
Full PPE in theatre—shoe covers, impermeable gowns, surgical or
N-95masks, protective head covering, gloves and eye protection
Closed smoke evacuation or filtration system with ultra-low partic-
ulate air filtration capability
Restricted movement of personnel in and out of the operating room Suction desufflation of abdomen
Trainee participation should be limited and include only essential
personnel
Avoid rapid desufflation, i.e. with specimen removal
Minimise CO2 leakage from trocars
Minimise blood/fluid droplet spray
Vaginal and open surgery: non-electrosurgical techniques where
possible
Low power setting, avoidance of long desiccation times
Smoke evacuators alongside ULPA filters
Suction device to remove surgical plume
Minimize blood/fluid droplet spray or spread
[16] Enhanced recovery Limit intra-abdominal pressure
Balloon trocars to minimize CO2 leak
Smoke extractors
Suction of CO2 for desufflation
[30] Only urgent procedures to minimise inpatient stays Safety of minimally invasive surgery remains undetermined
Screening consultation prior to procedure—symptoms in last 2
weeks, any travel
Test patients and clinical team prior to procedure
Positive pressure on hold during procedure and restarted 20 min
after patient leaves
Limited personnel in theatre
[5] Recommend only high priority/emergency cases, experienced sur-
geon
Low insufflation pressure
Minimal staff numbers, no observers Suction of gas prior to removing ports
Intubation and extubation in negative pressure room Smoke evacuation system capable of filtering aerosolized particles
from CO2 should be provided for laparoscopic surgery
Use low cautery settings
Avoid monopolar or advanced bipolar where possible
If monopolar use smoke evacuator
No clear evidence to favour open or laparoscopic
Consider treating intermediate priority patients if capacity available
but not during COVID surge
Follow local recommendations to test staff and patients for COVID
Follow local recommendations for PPE
Wear full PPE for COVID-positive patients as per WHO guidance
[31] All invasive procedures under GA deferred
[19] All elective cases deferred
Aim for same-day discharge where possible
Spinal anaesthesia in preference to general anaesthesia, unlikely to
greatly increase voiding dysfunction
[25] Transmission of fomites during vaginal surgery appears highly
unlikely
Regional anaesthesia preferable to general anaesthesia—lower risk
postoperative retention, reduces aerosol generation
[36] Augmentation cystoplasty, cystectomy, and continent and
incontinent diversions all postponed owing to high-dependency
in-patient care required
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urodynamics. All urodynamics and cystoscopy for benign in-
dications should be deferred. See Table 5 for a summary of
guidance for haematuria, bladder pain syndrome and outpa-
tient procedures.
Recommendations regarding surgery advise regional or lo-
cal anaesthesia where possible, in order to reduce aerosol gen-
eration with general anaesthesia [2, 19, 25, 28]. Screening for
COVID-19 symptoms and testing preoperatively is advised,
as evidence has shown poorer surgical outcomes for asymp-
tomatic COVID-19 patients, therefore surgery may worsen or
accelerate progression [2, 4, 5, 8, 14, 21, 28, 30]
Although better able to maintain physical distance and po-
tentially shorter hospital stays with laparoscopic surgery than
with open surgery [8], no evidence is available to support a
specific route of surgery; therefore, this is at the surgeon’s
discretion [5, 20].
Recommendations to reduce horizontal transmission in
surgery include having essential staff only in theatre, low
electrocautery settings, closed smoke evacuation and
minimising blood and fluid droplet spray [4, 5, 8, 14, 16, 20,
27, 28]. See Table 6 for a summary of guidance for elective
surgery and techniques to minimise horizontal transmission.
Continuing or restarting surgery during the pandemic re-
quires prioritisation of cases, taking into account the severity
of the pathology, patient comorbidities and the impact on
physical and mental health and quality of life. Seven docu-
ments specified prioritisation guidance. See Table 7 for a sum-
mary of the prioritisation of surgery.
Strengths
We followed a standardised rapid review methodology in or-
der to provide a summary of recommendations and practice
guidelines in a timely manner. We performed a comprehen-
sive literature search including published articles, articles in
press and association guidelines to ensure that we identified
and included all available evidence regarding management of
urogynaecology patients during the COVID-19 pandemic.
There is a high degree of consensus regarding the use of
virtual clinics, management outpatient procedures, and surgical
techniques to minimise horizontal transmission of COVID-19.
However, variations in recommendations exist and are
summarised in this review. Therefore, it can be used as a
resource to support adjustments in practice as local conditions
evolve.
As further evidence emerges, resources change and the
pandemic continues, this synthesis of available guidance can
be used as a reference for clinicians to guide management.
Limitations
Given the aim to issue a summary without delay using rapid
review methodology, some studies may have been omitted,
which is an inherent limitation of rapid reviews. There is sus-
ceptibility to bias in streamlining a systematic review process,
for example, in choosing studies for inclusion or exclusion
and in data extraction, as fewer independent reviewers con-
duct each step.
Recommendations are predominantly based on expert
opinion and, given the rapidly evolving nature of the
COVID-19 virus, there is often a lack of robust scientific
evidence [8] for clinically relevant questions.
Indeed, the COVID-19 “infodemic” has been described by
WHO as an “overabundance of information—some accurate





Elective surgery and consent Surgical techniques to minimise horizontal transmission
[21] Screen all patients with health questionnaire
Swab test before all elective surgery
All team members trained in appropriate use of PPE
Reduce all team members in theatre
If COVID positive, operate once fully recovered, i.e. asymptomatic
and two negative tests at 24-h interval
[32] Ideal is virtual consultation with electronic consent including
pre-printed information and patient’s electronic signature
Requires development with GMC and MHRA
Consent signed on day of procedure may lead to inadequate
consent and litigation
RCOG Royal College of Obstetricians and Gynaecologists, BSGE British Society for Gynaecological Endoscopy, EAU European Association of
Urology, PPE personal protection equipment, GA general anaesthesia, AGP aerosol-generating procedure, GMC General Medical Council, MHRA
Medicines and Healthcare Products Regulatory Authority, ULPA ultra-low particulate air, GI gastrointestinal, WHO World Health Organisation
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Table 7 Summary of prioritisation of surgery
Reference Prioritisation of surgery
[28] Emergency <1 h: life-threatening emergencies
Urgent <24 h: e.g. haemorrhage after functional urology surgery, urinary retention, unable to place catheter, surgical site or device infection
Urgent elective <4 weeks: e.g. second stage of SNS, disabling refractory BPS, Botox in high-risk neurogenic bladder patients, urinary
diversion in urinary fistula with severe complications
Elective, intermediate priority, 1–3 months: e.g. Botox in low-risk neurogenic bladder, bladder outlet obstruction due to mesh, removal of
vaginally extruded uninfected mesh, prolapse with complications, e.g. retention, hydronephrosis
Elective, low-priority, >3 months: e.g. refractory OAB, elective SUI surgery, BPS, elective prolapse surgery, urethral diverticulum without
complications, uncomplicated neurogenic bladder
[8] 1a: emergency <24 h to save life
1b: urgent <72 h as life-threatening condition
2: is required within <4 weeks with expectation of cure
3: can defer for 10–12 weeks with no predicated negative outcome
Enhanced recovery pathways: delay any oncology surgery by at least 15 days if COVID-19 symptoms preoperatively
[16] A: continue, e.g. second-stage neuromodulation, intravesical Botox for neurogenic bladder with risk of high bladder pressure, surgery for
grade 4 prolapse with acute renal failure and failed pessary
B: 1–8 weeks, e.g. refractory OAB and bladder cancer risk factors
C: delay 8–16 weeks, e.g. intravesical Botox
D: can be delayed >16 weeks, e.g. stress urinary incontinence surgery
[29] 1: urgent, <1 month—delay could cause major harm, e.g. prolapse beyond hymen with voiding dysfunction or upper renal tract compli-
cations
2: essential elective, <3 months—increased risk of adverse outcomes if delayed for undetermined time period, e.g. prolapse beyond hymen
with progressive symptoms, impaired QoL, failed pessaries but no upper renal tract complications
3: non-essential elective, postpone up to 1 year—not time sensitive, e.g. prolapse beyond hymen with no upper renal tract complications and
able to use pessary
Continence surgery: non-essential elective, unless failure of conservative and progressive symptoms
[21] Category 1: urgent: within 30 days, potential to deteriorate and become an emergency
Category 2: semi-urgent: within 60 days, causes pain dysfunction or disability, but unlikely to deteriorate quickly, unlikely to become an
emergency
Category 3: elective: within 365 days, causes pain dysfunction or disability, unlikely to deteriorate quickly, does not have potential to
become emergency
All urogynaecology cases are category 3, should be postponed. Can start in highly symptomatic patients when risk of transmission reduces,
depending on local situations
[5] Low priority: clinical harm very unlikely if postponed for 6 months, e.g. stress or urge incontinence surgery, surgery for urethral diverticula
Intermediate: clinical harm possible if postponed for 3–4 months but unlikely, e.g. surgical management of patients with urinary retention,
intravesical Botox for selected cases of neurogenic bladder
High priority: clinical harm likely if postponed for over 6 weeks, e.g. cystoscopy for macroscopic haematuria
Emergency: life-threatening situation and likely to have presented in ED despite pandemic
[18]
Tier 1: non-life-threatening illness, low acuity, i.e. SUI surgery, laparoscopic sacrocolpopexy, native tissue transvaginal prolapse surgery,
asymptomatic mesh exposure
Tier 2: non-life-threatening, but potential for near future morbidity or mortality, intermediate acuity, i.e. fistula repair, mesh-related
complication, e.g. severe pain/infection
Tier 3: high potential for near future morbidity or mortality, severe impairment of QoL, high acuity, i.e. prolapse with upper tract obstruction
and unable to retain pessary, obstructed voiding after MUS
Tier 4: emergency surgery
Each tier has subsets A and B
Subset B denotes patients with comorbidities that may be deferred until after lower acuity patients
EAU European Association of Urology, BPS bladder pain syndrome, OAB overactive bladder, SUI stress urinary incontinence, ED emergency depart-
ment, MUS mid-urethral sling, QoL Quality of life
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This is an inherent limitation of all reviews in this area
given the unprecedented public health crisis and the epidemi-
ological characteristics of the current pandemic.
As the COVID-19 pandemic continues, and our under-
standing and resources change, there is high potential for
modifications within recommendations and publication of fur-
ther guidance, which may have already occurred during pub-
lication of this rapid review.
Conclusion
The COVID-19 pandemic has changed the way in which we
conduct healthcare and will do so for the foreseeable future.
Evidence suggests that a large proportion of urogynaecological
conditions might be able to be managed using virtual consulta-
tions utilising behavioural measures, lifestyle changes and med-
ical therapy. Outpatient procedures in one-stop clinics to investi-
gate and treat conditions such as refractory OAB can be
maximised to avoid inpatient admissions, and to reduce the fre-
quency of visits and the use of general anaesthesia.
Technology is required to maintain and develop the quality
of virtual consultations and this is particularly important for
remote teaching of clean intermittent self-catheterisation,
home trial without catheter, pessary management and triaging
symptoms. For those unable to use or without access to the
required technology, smaller ad hoc face-to-face clinics with
PPE and physical distancing should be considered.
Various healthcare providers and organisations have devel-
oped and published guidance for practice, which should al-
ways be observed, as it is linked and adapted to local policies,
sociodemographic and epidemiological conditions, as well as
infrastructures. This review is aimed at providing a wider per-
spective on practice recommendations that have been pub-
lished to date and can be adapted or even considered for im-
plementation at local levels.
Although adaptations and provisions are being made to
manage urogynaecological conditions, given that the majority
of patients are elderly with comorbidities that increase risk of
COVID-19 morbidity and mortality, and with most surgical
procedures for quality of life, the resumption of elective activ-
ity is expected to be slow. Consequently, there is likely to be a
significant impact on quality of life within this cohort of pa-
tients and the impact of delayed diagnosis and treatment on
the trajectory of the disease is yet to be determined.
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